• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Ireland·Consumer Cyclical·GL9.IR
Share

Glanbia plc Stocks

€ 21.56Last Updated 16.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

€ 6.03B

€ 21.56
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

20.06.2026 16:01

Small caps last week: Anthropic IPO beneficiaries, GLP-1 craze winners, biotech rally

17.06.2026 17:50

Protein-powder maker Glanbia seen as rare food-sector beneficiary of GLP-1 craze

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating globally as a prominent nutrition company, Glanbia plc specializes in the development and distribution of sports and lifestyle nutrition products. These offerings come in various forms, including powdered supplements, ready-to-eat bars, convenient snacking foods, and prepared beverages. The company reaches consumers through a wide array of distribution channels, encompassing specialty retailers, online platforms, fitness centers, and larger retail environments such as food, drug, mass-market, and club stores. Additionally, Glanbia is a key producer of cheese, a diverse range of dairy and non-dairy nutritional and functional ingredients, and vital vitamin and mineral premixes. Its operational scope extends beyond product manufacturing to include activities such as financing, research and development, property management, receivables handling, general business administration, property leasing, various business services, and weight management solutions. The company boasts a robust portfolio of renowned brands, including OPTIMUM NUTRITION, SlimFast, BSN, ISOPURE, NUTRAMINO, think!, Amazing Grass, and BODY&FIT. Glanbia plc was founded in 1964 and maintains its corporate headquarters in Kilkenny, Ireland.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of GL9.IR is 24.6 and suggests 14.2% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.09.2026 19:55

"They're playing with our lives": What is known about the mathematician who called for a slowdown in the AI race

17.09.2026 19:13

Nebius shares rose 11% following a price increase for AI chips. What might this indicate?

17.09.2026 18:41

The Nasdaq jumped more than 1% on the back of falling oil prices and bond yields

17.09.2026 18:11

Is the Rally Stalling? How a Fed Rate Hike Could Affect the Markets

17.09.2026 17:40

Shares of a small-cap biotech newcomer soared to a record high. What inspired investors?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026